Genocea Reports Third Quarter 2015 Financial Results
On October 7, 2015, Genocea reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for...
View ArticleGenocea Presents Positive Findings from ATLASTM Immuno-Oncology Research …
Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus, and...
View ArticleGenocea to Present at the Piper Jaffray 27th Annual Healthcare Conference
Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus, and...
View ArticleGenocea to Present at the Stifel 2015 Healthcare Conference
Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus, and...
View ArticleWhat I Like About Genocea
The therapeutic vaccine candidate is currently in Phase II for the treatment of genital herpes infections. Data from Phase 1/2a trial so far has been encouraging. Most recent data from the Phase II...
View ArticleGenocea to Present at 2016 BIO CEO & Investor Conference
Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus, and...
View ArticleGenocea to Host Fourth Quarter and Year End 2015 Financial Results Conference …
Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus, and...
View ArticleGenocea Reports Fourth Quarter and Year-End 2015 Financial Results
In October, we demonstrated significant and durable Phase 2 efficacy for GEN-003, potentially positioning it to become the cornerstone treatment for the millions of people who suffer from genital...
View ArticleGenocea Doses Patients in Phase IIb Study on GEN-003
According to the World Health Organization (WHO), more than 400 million people across the world are affected by genital herpes. As treatment options for genital herpes are limited, Genocea estimates...
View ArticleGenocea Congratulates Dr. George Siber, 2016 Albert B. Sabin Gold Medal Award …
Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus (development...
View ArticleGenocea to Host First Quarter 2016 Financial Results Conference Call & Webcast …
Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus (currently...
View Article
More Pages to Explore .....